European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology..
AIMS: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity.
METHODS AND RESULTS: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy.
CONCLUSION: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
European heart journal. Quality of care & clinical outcomes - 9(2022), 1 vom: 13. Dez., Seite 1-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, G A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Assessment |
|---|
| Anmerkungen: |
Date Completed 14.12.2022 Date Revised 10.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ehjqcco/qcac070 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348300824 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348300824 | ||
| 003 | DE-627 | ||
| 005 | 20240210232447.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ehjqcco/qcac070 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM348300824 | ||
| 035 | |a (NLM)36316010 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, G A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.12.2022 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. | ||
| 520 | |a AIMS: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity | ||
| 520 | |a METHODS AND RESULTS: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy | ||
| 520 | |a CONCLUSION: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Assessment | |
| 650 | 4 | |a Cancer therapy-related cardiovascular toxicity | |
| 650 | 4 | |a Cardio-oncology | |
| 650 | 4 | |a Outcomes | |
| 650 | 4 | |a Quality indicators | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a Aktaa, S |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, E |e verfasserin |4 aut | |
| 700 | 1 | |a Gale, C P |e verfasserin |4 aut | |
| 700 | 1 | |a Yaseen, Israa F |e verfasserin |4 aut | |
| 700 | 1 | |a Gulati, G |e verfasserin |4 aut | |
| 700 | 1 | |a Asteggiano, R |e verfasserin |4 aut | |
| 700 | 1 | |a Szmit, S |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen-Solal, A |e verfasserin |4 aut | |
| 700 | 1 | |a Abdin, A |e verfasserin |4 aut | |
| 700 | 1 | |a Jurczak, W |e verfasserin |4 aut | |
| 700 | 1 | |a Garrido Lopez, P |e verfasserin |4 aut | |
| 700 | 1 | |a Sverdlov, A L |e verfasserin |4 aut | |
| 700 | 1 | |a Tocchetti, C G |e verfasserin |4 aut | |
| 700 | 1 | |a Barac, A |e verfasserin |4 aut | |
| 700 | 1 | |a Parrini, I |e verfasserin |4 aut | |
| 700 | 1 | |a Zamorano, P |e verfasserin |4 aut | |
| 700 | 1 | |a Iakobishvili, Z |e verfasserin |4 aut | |
| 700 | 1 | |a Pudil, R |e verfasserin |4 aut | |
| 700 | 1 | |a Badimon, L |e verfasserin |4 aut | |
| 700 | 1 | |a Kirby, A M |e verfasserin |4 aut | |
| 700 | 1 | |a Blaes, A H |e verfasserin |4 aut | |
| 700 | 1 | |a Farmakis, D |e verfasserin |4 aut | |
| 700 | 1 | |a Curigliano, G |e verfasserin |4 aut | |
| 700 | 1 | |a Stephens, R |e verfasserin |4 aut | |
| 700 | 1 | |a Lyon, A R |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez-Fernandez, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal. Quality of care & clinical outcomes |d 2015 |g 9(2022), 1 vom: 13. Dez., Seite 1-7 |w (DE-627)NLM259053279 |x 2058-1742 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g number:1 |g day:13 |g month:12 |g pages:1-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ehjqcco/qcac070 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 |e 1 |b 13 |c 12 |h 1-7 | ||